61 related articles for article (PubMed ID: 1803608)
1. [The prognostic assessment of patient survival in chronic myeloleukemia].
Petukhov VI; Bondar' DK; Rastrigin VL
Ter Arkh; 1991; 63(12):73-7. PubMed ID: 1803608
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic significance of some clinical and laboratory parameters in patients with chronic myelogenous leukemia].
Sledziowski P; Lisiewicz J
Przegl Lek; 1995; 52(2):42-6. PubMed ID: 7784614
[TBL] [Abstract][Full Text] [Related]
3. [The prognostic factors in chronic myeloleukemia].
Khoroshko ND
Ter Arkh; 1993; 65(7):23-8. PubMed ID: 8211773
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
5. Multivariate analysis of prognostic factors in chronic myelogenous leukemia.
Jootar S; Chuncharunee S; Ongphiphaphadhanakul B; Atichartakarn V
J Med Assoc Thai; 1990 Dec; 73(12):662-9. PubMed ID: 2086713
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
Onida F; Ball G; Kantarjian HM; Smith TL; Glassman A; Albitar M; Scappini B; Rios MB; Keating MJ; Beran M
Cancer; 2002 Oct; 95(8):1673-84. PubMed ID: 12365015
[TBL] [Abstract][Full Text] [Related]
7. [Long-term survival in chronic myeloid leukemia: frequency and fundamental characteristics in a series of 100 patients].
Cervantes F; Bosch F; Terol MJ; Pereira A; Rozman C
Sangre (Barc); 1993 Apr; 38(2):93-6. PubMed ID: 8516734
[TBL] [Abstract][Full Text] [Related]
8. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
9. Estimation of chronic phase duration in Ph-positive chronic myelocytic leukemia treated with busulfan: statistical analysis on Japanese patients.
Hashimoto T; Ohtaki M; Ueoka H; Munaka M; Kuramoto A; Kamada N
Int J Hematol; 1994 Jul; 60(1):59-69. PubMed ID: 7919239
[TBL] [Abstract][Full Text] [Related]
10. [Katarjian's prognostic model in prognosing chronic myelogenous leukemia at diagnosis and after one year of disease duration].
Zaucha JM; Kaczmarek J; Hellmann A
Acta Haematol Pol; 1993; 24(2):139-46. PubMed ID: 8372613
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
[TBL] [Abstract][Full Text] [Related]
12. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
13. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia.
Prejzner W
Med Sci Monit; 2002 May; 8(5):BR193-7. PubMed ID: 12011769
[TBL] [Abstract][Full Text] [Related]
14. Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.
Hess G; Meyer RG; Schuch B; Bechthold K; El-Kholy I; Huber C
Am J Hematol; 2008 Mar; 83(3):178-84. PubMed ID: 17876770
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
[TBL] [Abstract][Full Text] [Related]
16. Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia.
Rodriguez J; Cortes J; Talpaz M; O'Brien S; Smith TL; Rios MB; Kantarjian H
Clin Cancer Res; 2000 Jan; 6(1):147-52. PubMed ID: 10656443
[TBL] [Abstract][Full Text] [Related]
17. The cytogenetic response as a surrogate marker of survival.
Rosti G; Testoni N; Martinelli G; Baccarani M
Semin Hematol; 2003 Apr; 40(2 Suppl 2):56-61. PubMed ID: 12783377
[TBL] [Abstract][Full Text] [Related]
18. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2935-8. PubMed ID: 9329568
[TBL] [Abstract][Full Text] [Related]
20. [The intensification of the therapy of chronic myeloleukemia by taking into account the factors prognostic of the course of the disease].
Khoroshko ND
Ter Arkh; 1994; 66(7):30-5. PubMed ID: 7985125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]